Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 14/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14093295 | 0.93 | MEN1 (0.51) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3686862 | 0.88 | CHRM5 (0.56) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL986997 | 0.86 | MAPT (0.54) | MEN1RAB9AKMT2ANPC1TNF | |
| SCHEMBL986835 | 0.84 | MAPT (0.54) | MEN1RAB9AKMT2ANPC1TNF | |
| SCHEMBL17474558 | 0.84 | CHRM5 (0.65) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL14432694 | 0.83 | MAPT (0.49) | MEN1RAB9AKMT2ANPC1TNF | |
| SCHEMBL3200738 | 0.83 | CHRM5 (0.73) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL17474536 | 0.83 | CHRM5 (0.76) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10101309 | 0.82 | MAPT (0.49) | MEN1RAB9AKMT2ANPC1TNF | |
| SCHEMBL3825106 | 0.82 | SMN1; SMN2 (0.54) | MEN1RAB9AKMT2ANPC1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338163-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHAMACEUTICALS CORP. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
| EP-2185514-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009017831-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338163-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | CHRM5 2919/4885CHRM1 4118/4885CHRM2 3754/4885 |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | CHRM5 2919/4885CHRM1 4118/4885CHRM2 3754/4885 |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | CHRM5 2919/4885CHRM1 4118/4885CHRM2 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.